NYSE:ABBVBiotechs
What AbbVie (ABBV)'s New IBD Data for SKYRIZI and RINVOQ Means For Shareholders
In early May 2026, AbbVie reported that shareholders voted against a proposal to require an independent board chair while the company highlighted extensive new real‑world and long‑term data for its key immunology drugs SKYRIZI and RINVOQ in inflammatory bowel disease.
The combination of fresh efficacy and quality‑of‑life data for these therapies and continued conference outreach underscores how central immunology remains to AbbVie’s business profile.
We’ll now examine how AbbVie’s latest...